Last reviewed · How we verify
Dexamethasone lipid microsphere plus ropivacaine — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Dexamethasone lipid microsphere plus ropivacaine (Dexamethasone lipid microsphere plus ropivacaine) — Beijing Tiantan Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dexamethasone lipid microsphere plus ropivacaine TARGET | Dexamethasone lipid microsphere plus ropivacaine | Beijing Tiantan Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dexamethasone lipid microsphere plus ropivacaine CI watch — RSS
- Dexamethasone lipid microsphere plus ropivacaine CI watch — Atom
- Dexamethasone lipid microsphere plus ropivacaine CI watch — JSON
- Dexamethasone lipid microsphere plus ropivacaine alone — RSS
Cite this brief
Drug Landscape (2026). Dexamethasone lipid microsphere plus ropivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-lipid-microsphere-plus-ropivacaine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab